Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announced that it has entered into an option and license agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) for two preclinical vaccine candidates. The agreement expands the companies’ current collaboration.